Astellas XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global urology devices market is projected to reach USD 46,408.2 million by 2026 from USD 38,005.6 million in 2021, at a CAGR of 4.1%.
Market growth is driven by factors such as the growing number of hospitals and investments in endoscopy and laparoscopy facilities, rising incidence and prevalence of urological conditions, and growing preference for minimally invasive procedures. On the other hand, the high degree of market consolidation is expected to limit market growth to a certain extent in the coming years.
The consumables & accessories segment accounted for the highest growth rate in the urology devices market, by product, during the forecast period
EMUC 2020: Neoadjuvant Versus Adjuvant Strategies in Locally Advanced Bladder Cancer
(UroToday.com) In an oral presentation in a session examining neoadjuvant versus adjuvant strategies in locally advanced bladder cancer at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Andrea Necchi led a discussion of neoadjuvant strategies in advanced bladder cancer.
He began highlighting muscle invasive bladder cancer (MIBC) as a model for clinical research based on high rates of relapse and mortality following surgical intervention alone, the relatively poor use of neoadjuvant chemotherapy in spite of international guidelines, the poor prognosis of patients with residual MIBC following neoadjuvant chemotherapy, and the uncertainty of treatment approaches in patients who are ineligible for cisplatin.